Visiongain has published a new report entitled Healthcare Cold Chain Logistics Market Report 2025-2035: Forecasts by Product (Biopharmaceuticals, Vaccines, Clinical Trial Materials, Others), by Services (Transportation, Storage, Packaging, Others), by Mode of Transport (Air Transport, Ground Transport, Water Transport), by Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Frozen), by End-users (Biopharmaceutical and Biotechnology Companies, Hospitals and Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global healthcare cold chain logistics market is estimated at US$25.37 billion in 2025 and is projected to grow at a CAGR of 11.1% during the forecast period 2025-2035.

Increasing Drug Development Activities by Pharmaceutical and Biopharmaceutical Companies

The increasing focus on biological drug development is driving significant demand for cold chain logistics services in the pharmaceutical industry. Biologics currently make up about one-third of pharmaceutical pipelines, and this proportion is expected to grow over the next decade. Since these drugs, including cell and gene therapies, require strict temperature-controlled storage and transportation, specialized cold chain solutions are becoming essential. AstraZeneca’s recent US$1 billion acquisition of EsoBiotec on March 17, 2025, highlights this trend, as it aims to strengthen its cell therapy capabilities in cancer and autoimmune diseases. Additionally, pharmaceutical companies are expanding clinical trials to emerging markets to reduce costs, further complicating cold chain distribution for trial materials and increasing reliance on third-party logistics providers.

How will this Report Benefit you?

Visiongain’s 344-page report provides 135 tables and 189 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the vaccine contract manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for healthcare cold chain logistics. Get financial analysis of the overall market and different segments including product, service, mode of transport, holding temperature range, end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing healthcare cold chain logistics market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Integration of AI and Machine Learning (ML) in Healthcare Cold Chain Logistics

The integration of AI and machine learning (ML) is also transforming drug development and logistics management. Amgen, for instance, has doubled its clinical trial enrollment speed using an ML-driven data analytics tool, while Sanofi’s collaboration with OpenAI is streamlining patient recruitment timelines. These advancements are not only accelerating drug development but also necessitating more agile and scalable cold chain logistics networks. Contract Manufacturing Organizations (CMOs) in the U.S. and EU stand to benefit the most, given their expertise in manufacturing highly potent biologics. As personalized medicine and orphan drug development grow, smaller logistics providers can compete by offering specialized services, ensuring efficient and compliant transportation of these innovative treatments.

Rising Globalisation of Clinical Trials

The globalization of clinical trials is significantly transforming the healthcare cold chain logistics market, as pharmaceutical companies expand studies across multiple regions. This widespread distribution necessitates sophisticated temperature-controlled logistics to maintain the stability and efficacy of sensitive medical products. For instance, UPS has strengthened its healthcare logistics operations through the acquisition of German firms Frigo-Trans and BPL, enhancing its temperature-controlled capabilities across Europe. This move aligns with the growing industry demand for robust cold chain infrastructure, particularly after the COVID-19 pandemic highlighted the need for efficient vaccine and biologics distribution.  

Similarly, CRYOPDP, a global provider specialising in temperature-controlled logistics for clinical trials, has expanded its operations to support the increasing international reach of pharmaceutical research. With 24 facilities across 14 countries and a logistics network spanning over 150 countries, CRYOPDP ensures consistent service quality worldwide, a critical factor in managing complex global trials. Such expansions play a crucial role for pharmaceutical firms running trials in diverse regulatory settings, guaranteeing that vaccines, biologics, cell therapies, gene therapies, and other temperature-sensitive medications remain effective throughout the distribution process.

Where are the Market Opportunities?

Increasing Strategic Initiatives Among Market Players

The healthcare cold chain logistics sector is witnessing a surge in strategic initiatives as major players enhance their manufacturing, storage, and transportation capabilities to comply with stringent global regulations. Pharmaceutical manufacturers and specialized logistics companies are forming collaborations, launching new services, and entering agreements to improve the storage and transport of temperature-sensitive biologics. For instance, FedEx expanded its healthcare logistics presence in the UAE on 25 February 2025, launching advanced solutions for pharmaceuticals, medical equipment, and research companies. Also, on 16 January 2025, Delhivery introduced Rapid Commerce, a sub-2-hour fulfillment service, initially launched in Bengaluru, which is already handling 300+ orders daily. These developments highlight how logistics companies are adapting to growing healthcare demands, embracing sustainability, speed, and efficiency in cold chain transportation.

Competitive Landscape

The major players operating in the vaccine contract manufacturing market are A.P. Moller – Maersk, Atelerix Ltd, Cavalier Logistics Inc., Catalent, Inc., Cardinal Health, Cencora, Inc., CEVA Logistics, DB Schenker, Delhivery Limited, DHL Group, FedEx, Kuehne+Nagel, Marken (A UPS Company), NMDP BioTherapies, Thermo Fisher Scientific Inc., United Parcel Services (UPS), and YUSEN LOGISTICS CO., LTD. These major players operating in this market have adopted various strategies comprising M&A, collaborations, investment in R&D, regional business expansion, partnerships, and new product launch.

Recent Developments

• On 4 March 2025, Yusen Logistics Philippines Inc. (YLPH) inaugurated a new Supply Chain Solutions (SCS) office in the Philippines, underscoring its commitment to innovation and excellence in logistics services.
• On 3 March 2025, Sanofi formed a partnership with Kuehne+Nagel for the fulfillment, handling, and value-added services of pharmaceutical and consumer health products in Turkey.
• On 24 February 2025, FedEx strengthened its position in the UAE’s expanding healthcare sector by providing innovative logistics solutions specifically designed for pharmaceuticals, medical equipment, and medical research companies.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.